Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

BACKGROUND: The international, phase 3 COMPARZ study demonstrated that pazopanib and sunitinib have comparable efficacy as first-line therapy in patients with advanced renal cell carcinoma, but that safety and quality-of-life profiles favor pazopanib. Our report analyzed pazopanib and sunitinib safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Jun, Jin, Jie, Oya, Mototsugu, Uemura, Hirotsugu, Takahashi, Shunji, Tatsugami, Katsunori, Rha, Sun Young, Lee, Jae-Lyun, Chung, Jinsoo, Lim, Ho Yeong, Wu, Hsi Chin, Chang, Yen Hwa, Azad, Arun, Davis, Ian D., Carrasco-Alfonso, Marlene J., Nanua, Bhupinder, Han, Jackie, Ahmad, Qasim, Motzer, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964681/
https://www.ncbi.nlm.nih.gov/pubmed/29788981
http://dx.doi.org/10.1186/s13045-018-0617-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964681/
https://www.ncbi.nlm.nih.gov/pubmed/29788981
http://dx.doi.org/10.1186/s13045-018-0617-1

Ejemplares similares